New pathogenic germline variants identified in mesothelioma

Laila Belcaid*, Birgitte Bertelsen, Karin Wadt, Ida Tuxen, Iben Spanggaard, Martin Højgaard, Jens Benn Sørensen, Jesper Ravn, Ulrik Lassen, Finn Cilius Nielsen, Kristoffer Rohrberg, Christina Westmose Yde

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

1 Citation (Scopus)
15 Downloads (Pure)

Abstract

Background: Mesothelioma (MM) is associated with asbestos exposure, tumor heterogeneity and aggressive clinical behavior. Identification of germline pathogenic variants (PVs) in mesothelioma is relevant for identifying potential actionable targets and genetic counseling. Methods: 44 patients underwent whole exome sequencing (WES) or whole genome sequencing (WGS). Germline variants were selected according to association with inherited cancer using a 168-gene in silico panel, and variants classified according to ACMG/AMP classification as pathogenic (class 5) or likely pathogenic (class 4). Results: In total, 16 patients (36%) were found to carry pathogenic or likely pathogenic variants in 13 cancer associated genes (ATM, BAP1, BRCA2, CDKN2A, FANCA, FANCC, FANCD2, FANCM, MUTYH, NBN, RAD51B, SDHA and XPC). The germline PVs occurred in DNA repair pathways, including homologous recombination repair (HRR) (75%), nucleotide excision repair (6%), cell cycle regulatory (7%), base excision repair (6%), and hypoxic pathway (6%). Five (31%) patients with a germline PV had a first or second degree relative with mesothelioma compared to none for patients without a germline PV. Previously undiagnosed BRCA2 germline PVs were identified in two patients. Potential actionable targets based on the germline PVs were found in four patients (9%). Conclusion: This study revealed a high frequency of germline PVs in patients with mesothelioma. Furthermore, we identified germline PVs in two genes (NBN & RAD51B) not previously associated with mesothelioma. The data support germline testing in mesothelioma and provide a rationale for additional investigation of the HRR pathway as a potential actionable target.

Original languageEnglish
Article number107172
JournalLung Cancer
Volume179
Number of pages8
ISSN0169-5002
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Author(s)

Keywords

  • Cancer genetics
  • Germline variants
  • Homologous recombination pathway
  • Mesothelioma
  • Precision oncology

Cite this